Osimertinib is more effective as first-line therapy than other EGFR inhibitors for patients with advanced EGFR-mutated non–small cell lung cancer—notably Asians, who have a higher incidence of the disease compared with Western populations. The conclusion is based on data from a subgroup analysis of the phase III FLAURA trial.
http://ift.tt/2COmgIO
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου